Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has initiated a Phase 2b clinical trial with AZ-104 (Staccato loxapine) in billet with migraine headaches. AZ-104 is a lower-dose version of AZ-004 (Staccato loxapine), Alexza's lead product seeker that is in late Phase 3 clinical evolvement for the acute head injuries & strokes: ukwww.royalbucks.co.uk
copyrights:cite this source roget's ii: the new thesaurus of agitation in clients with schizophrenia or bipolar disorder.

More: - Continued here